Remove 2025 Remove FDA Remove Patient Care
article thumbnail

GLP-1s Effective as Adjunctive Therapy in Patients with T1D, Obesity | ADA 2025

Drug Topics

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were safe and effective as adjunctive therapies for patients with type 1 diabetes (T1D) and overweight or obesity, according to an abstract presented at the American Diabetes Association 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. References 1.

article thumbnail

FDA Approves Insulin Aspart-Xjhz as First Interchangeable Biosimilar to NovoLog

Drug Topics

The FDA approved insulin aspart-xjhz (Kirsty) 100 units/mL as the first and only interchangeable biosimilar to insulin aspart (NovoLog). The biosimilar, a rapid-acting human insulin analog, is indicated for glycemic control in adults and pediatric patients with diabetes. July 15, 2025. Accessed July 21, 2025.

FDA 331
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The FDA approved nitisinone (Harliku) for the reduction of urine homogentisic acid (HGA) in patients with alkaptonuria (AKU). The medication is expected to launch in July 2025. REFERENCES 1.

FDA 341
article thumbnail

A Team Effort Is Needed for Inventory Management | McKesson ideaShare

Drug Topics

In an interview at McKesson ideaShare 2025, Thomas Sherrer, PharmD, co-owner of Poole's Pharmacy, highlighted that managing inventory is fundamentally a "team sport" that requires comprehensive involvement from all pharmacy staff. Effective pharmacy inventory management requires a collaborative and proactive approach.

article thumbnail

Smart Insulin Pen Cap System Shows Sustained Glycemic Improvement Over 12 Months | ADA 2025

Drug Topics

1 Smart Insulin Pen Cap System Shows Sustained Glycemic Improvement Over 12 Months | ADA 2025 / Orawan - stock.adobe.com The system, called the Bigfoot Unity Diabetes Management System, integrates with the FreeStyle Libre 2 sensor and supports commonly used insulin pens to simplify diabetes care. References 1.

article thumbnail

Gaps Remain in MOUD Access Across Opioid Treatment Programs

Drug Topics

They found that community pharmacists are key members of collaborative care models and can effectively lead buprenorphine initiation and ongoing patient care, expand access to treatment, and provide additional counseling for nonpharmacological treatment. March 18, 2025. Accessed June 30, 2025. March 25, 2025.

article thumbnail

Once Monthly Oral PrEP Medication Will Advance to Phase 3 Study

Drug Topics

In the EXPrESSIVE-11 trial, investigators will evaluate the safety and efficacy of the investigational drug with greater likelihood of HIV exposure in 16 countries, which will start enrolling in August 2025. July 14, 2025. Accessed July 16, 2025. Updated June 29, 2025. Accessed July 16, 2025. REFERENCES 1.